Biogen’s experimental Alzheimer’s therapy shows comparable slowing of cognitive decline in mid-stage trial, paving way to Phase 3

Biogen reported that its experimental Alzheimer’s drug slowed cognitive decline in a mid-stage study. The trial showed patients experienced a rate of decline similar to that seen with currently approved therapies.

The data suggest the novel approach may be as effective as existing treatments, offering a potential new option for patients with Alzheimer’s disease. Analysts noted the comparable efficacy strengthens the company’s development program.

Based on these results, Biogen plans to advance the candidate into a Phase 3 trial later this year, aiming to confirm the findings in a larger population.